Medical Device, Diagnostic, Digital Health Reimbursement
Medical Device, Diagnostic, Digital Health Regulatory Affairs
Medical Device, Diagnostic, Digital Health Clinical Trials
The JGS holistic approach takes into consideration the three facets of the commercialization process at once. Without simultaneously applying strategies for each plan, your technology may never make it to the U.S. marketplace. That’s why JGS creates customized commercialization plans for each of our clients.
Stay up-to-date with the latest news, events, and case studies.
Medicare Coverage and Payment of Virtual Services
We Love to Hear From You
You have questions? Contact us today, we’re here to help.
On the other hand we denounce with rightous indignation and dislike men who are so beguiled and demoralized by the charms of pleasure of the moment.
JGS has a high level of expertise in the reimbursement domain, which resonates in their ability to critically assess the reimbursement landscape and offer innovative solutions given previous experience. I highly recommend the opportunity to work with JGS.Kayla Wagner, Vice President – Product Management at Quadrant Biosciences Inc.
JGS came highly recommended by a mentor who was familiar with their extensive experience and knowledge of the US payer system. Jen spent time explaining the nuances of her recommendations and educating me about the US insurance industry; this was critical in enabling me to effectively articulate her findings to other stakeholders, including prospective investors and customers. Jen is a brilliant and invaluable asset to our team, having helped us navigate one of the more complicated aspects of medical device commercialization; I believe she and her team will be a fantastic addition to your group. I am excited to continue working with them as we develop our future clinical study protocols and ultimately pursue coverage of our device.Samantha I Scott, PhD CEO of JuneBrain, Inc.
"We were encouraged as part of our participation in the NCI Commercialization Acceleration Program to consider reimbursement early. Since our product, a topical, intra-operative nerve imaging agent, is innovative, having a code will be key to revenues. I was grateful to receive excellent support and crisp thinking from the team at JGS as to strategic options - in a superb report that we will be able to share with strategic partners as we progress"Constance McKee, President & CEO, Manzanita Pharmaceuticals, Inc.